Feds subpoena Merck on marketing of hepatitis, cancer drugs

Share this article:

Merck said it received a subpoena related to marketing and selling activities with respect to three drugs: Temodar, PegIntron and Intron A.

The subpoena, disclosed today in a regulatory filing, requests information related to the company's promotional activities from January 1, 2004, to the present, in “a federal healthcare investigation under criminal statutes.”

The company said it is cooperating with the Department of Justice investigation.

Global sales of Temodar, a treatment for brain tumors, were $1.07 billion in 2010. PegIntron, for treating hepatitis C, generated $737 million last year, while Intron A, marketed for chronic hepatitis B and C and numerous anticancer indications, had $209 million in 2010 sales.

Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.